Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Generic Tacrolimus vs Advagraf in Kidney Transplant Patients
NCT03978494Phase 1Withdrawn
- Sponsor
- Sandoz
- Start
- Sep 2019
- Primary completion
- May 2020
- Modality
- RNA-Targeting Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of tacrolimus in kidney transplant rejection (2 arms), sponsored by Sandoz. Primary endpoints: Area Under the Curve at Steady State over Dosing Interval at Day 21 and Maximum Plasma Concentration at Steady State at Day 21. Planned start Sep 2019; status: withdrawn.
02
Drugs
tacrolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT03978494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03978494.